Monitoring the efficacy and safety of lantus in t2 patients failing glycemic control with premix or NPH with OAD or short acting insulin

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012110411356N1

Enrollment

230

Registered

2012-11-18

Start date

2011-12-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes.

Interventions

glargyn(lantus) The investigator will determine the dosage of insulin glargine according to his needs & based on his other concomitant treatments. The insulin dosage of patients will be up titrated

glargyn(lantus) The investigator will determine the dosage of insulin glargine according to his needs & based on his other concomitant treatments. The insulin dosage of patients will be up titrat

Eligibility

Sex/Gender

All

Age

19 Years to 79 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: suffering from diabetes Mellitus type 2; agebetween 19 to 79 years ; patients who previously failed to achieve a glycemic control (HbA1c = 7 %; ADA, EASD.) under premixesi nsulin BD or NPH with OAD or short acting insulins and patients must sign the informed consent. Exclusion criteria: patients with severe renal failure and haemodialysis; patients with sever hepatic failure, pregnancy or breast feeding; mental disorders; hypersensitivity to basal insulin and inability to perform SMBG.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HbA1c level each visit. Timepoint: 24 weeks. Method of measurement: choromotography.	—

Secondary

Measure	Time frame
Proportion of patients reaching the glycemic control. Timepoint: 24 weeks. Method of measurement: choromatography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Mir

Sanofi Aventis

Elham.Mir@iran.sanofi-aventis.com+98 21 8864 9710

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026